Dear LarryS1751: For the post-operative adjuvant setting for node positive, hormone receptor negative breast cancer patients, dose-dense AC-T has shown itself to be superior to the same treatment regimen given every 3 weeks. Dose-dense AC-T has not been formally tested for preoperative treatment, but is a reasonable option. You may benefit by seeking a second opinion.